VRCA•benzinga•
Verrica Pharmaceuticals Reports 16.7% Sequential Growth In Q1 2025 With Over 10,000 YCANTH Dispensed Applicator Units And Expects Revenue To Align With Normalized Distributor Inventory Levels
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 7, 2025 by benzinga